Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first-in-class aminopeptidase-targeting peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells.
Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being evaluated in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study, the phase 1/2 combination study ANCHOR and the phase 2 Study BRIDGE.
The company plans for filing a New Drug Application (NDA) for accelerated approval of melflufen for the treatment of patients with triple-class refractory multiple myeloma based on data from the HORIZON study. The company targets to submit the application to the FDA in H1, 2020.
Oncopeptides’ headquarters is in Stockholm, Sweden with U.S. headquarters in Boston, Massachusetts, and in Mountain View, California. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.